Ludwig In the News

October 26, 2012

Epigenetic mechanisms influence processes from stem cell differentiation to cancer, and researchers are keen to understand how these events differ at the genomic scale—the so-called epigenome.

October 11, 2012

AstraZeneca’s biologics arm, MedImmune, is joining forces with two cancer organisations in a bid to advance the research of immunotherapy in cancer.

October 10, 2012
Fierce Biotech

Cancer immunotherapy research has once again topped the R&D charts as one of the hottest fields in biotech. And now MedImmune, the biologics arm of AstraZeneca ($AZN), has teamed up with some prestigious research teams to come up with some revved up combo therapies using a few of their most promising antibodies.

July 25, 2012
Clinical Sequencing News (PDF)

In a proof-of-principle study, the team evaluated the performance of their mRNA-seq protocol, called Smart-Seq, and used it to study single circulating tumor cells from melanoma.

July 3, 2012
New Scientist

Some junk is worth keeping. Non-coding, or junk, mouse DNA contains vast amounts of information vital to gene function—and those regulatory functions take up much more space on the genome than the all-important coding segments.

June 20, 2012
NBC San Diego

Treatment in animal subjects stopped the effects of Huntington’s and produced long-term improvement.

April 2, 2012
Scientific American

Few diseases have strong enough genetic components to make sequencing a solid way to assess individual risk.

March 7, 2012
U.S. News & World Report

In rare case, her immune system was spurred to eliminate tumors even in distant sites, researchers say.


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?